Oxford Immunotec has been developing and strengthening its expertise in T cell measurement for over 15 years since the introduction of its T-SPOT® technology (ELISPOT) in the field of TB diagnostics. The T-SPOT®.TB test is approved in over 60 countries, including US, EU, Japan and China. The research use-only T-SPOT Discovery SARS-CoV-2 assay uses this same T-SPOT technology to allow SARS-CoV-2-specific T cells to be detected and enumerated. The optimized antigen mix used in the test is based on SARS-CoV-2 structural proteins, with sequences of high homology to other coronaviruses removed. This allows the maximum breadth of the immune response to be measured, while minimizing cross reactivity. Oxford Immunotec’s single antigen-per-well approach also allows specific information about the immune response to different SARS-CoV-2 antigens to be gathered in parallel.
T-SPOT technology can be automated using the T-Cell Select™ reagent kit to accommodate variations in scale - automation solutions are available for low, medium andhigh throughput settings. The T-Cell Select reagent kit also enables sample stability of 54 hours to be achieved, simplifying sample logistics.